C12N 2501/195
Heregulin, neu differentiation factor
C12N2501/195 (Heregulin, neu differentiation factor) appears on 43 US grants and 72 published applications in this corpus.
Search patents in C12N- Granted patents
- 43
- Published applications
- 72
- Assignees
- 34
- Inventors
- 93
- Latest grant
- 25 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 3 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 4 |
| 2004 | 1 | 2 |
| 2005 | 2 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 2 |
| 2008 | 1 | 5 |
| 2009 | 1 | 3 |
| 2010 | 4 | 3 |
| 2011 | 1 | 2 |
| 2012 | 3 | 3 |
| 2013 | 3 | 4 |
| 2014 | 4 | 4 |
| 2015 | 2 | 4 |
| 2016 | 1 | 5 |
| 2017 | 2 | 1 |
| 2018 | 5 | 2 |
| 2019 | 1 | 3 |
| 2020 | 1 | 3 |
| 2021 | 1 | 3 |
| 2022 | 3 | 3 |
| 2023 | 0 | 2 |
| 2024 | 1 | 5 |
| 2025 | 1 | 4 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Scalable primate pluripotent stem cell aggregate suspension culture25 Feb 2025US 12,234,477 B2ViaCyte, Inc.
- Cell encapsulation device comprising a pancreatic progenitor cell population20 Feb 2024US 11,905,530 B2ViaCyte, Inc.
- Cryopreserved endocrine cells that express chromogranin A20 Sep 2022US 11,446,335 B2ViaCyte, Inc.
- Production of fully functional mature beta cells from human pancreatic progenitors12 Apr 2022US 11,299,711 B2The Regents of the University of California
- Materials and methods for generating therapeutic mesenchymal stem cells29 Mar 2022US 11,286,462 B2University of Kansas
- Cryopreserved endocrine cells that express chromogranin a1 Oct 2026US 2026/0294981 A1ViaCyte, Inc.
- Neuronal regeneration promoting cells (nrpcs) and treating damaged nerve cells30 Apr 2026US 2026/0115230 A1Cellatoz Therapeutics, Inc.
- Methods of producing a tumor avatar30 Apr 2026US 2026/0117192 A1Ariel Scientific Innovations Ltd.
- Medium and method for preparation of salivary gland organoid25 Sep 2025US 2025/0297217 A1Organoidsciences Ltd.
- Pharmaceutical composition for alleviation or treatment of cerebral infarction sequela12 Jun 2025US 2025/0186504 A1Industry-University Cooperation Foundation Hanyang University
Most cited
By later US patents
- In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells86US 8,859,286 B2ViaCyte, Inc. · 2014
- Stem cell aggregate suspension compositions and methods of differentiation thereof72US 8,008,075 B2ViaCyte, Inc. · 2011
- Methods for culturing pluripotent stem cells in suspension using ERBB3 ligands63US 8,211,699 B2ViaCyte, Inc. · 2012
- Compositions and methods useful for culturing differentiable cells58US 8,153,429 B2ViaCyte, Inc. · 2012
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010